Zealand Pharma major shareholder announcement: Bank of America Corporation
17 August 2024 - 2:05AM
UK Regulatory
Zealand Pharma major shareholder announcement: Bank of America
Corporation
Company announcement – No. 40 / 2024
Zealand Pharma major shareholder announcement: Bank of
America Corporation
Copenhagen, Denmark, 16 August
2024 – Zealand Pharma A/S (“Zealand”)
(Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based
biotechnology company focused on the discovery and development of
innovative peptide-based medicines, today reports prior receipt on
19 March 2024 and 5 April 2024 of notification pursuant to Section
38 of the Danish Capital Markets Act from the following major
shareholder:
As of 4 March 2024, Bank of America Corporation held nominally
3,253,781 shares (each share carrying one vote) in Zealand Pharma
A/S, corresponding to 5.21% of the total share capital and total
voting rights in Zealand Pharma A/S.
As of 2 April 2024, Bank of America Corporation held nominally
3,076,017 shares (each share carrying one vote) in Zealand Pharma
A/S, corresponding to 4.91% of the total share capital and total
voting rights in Zealand Pharma A/S.
Please see further details in the attached notification
forms.
# # #
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology
company focused on the discovery and development of peptide-based
medicines. More than 10 drug candidates invented by Zealand have
advanced into clinical development, of which two have reached the
market and three candidates are in late-stage development. The
company has development partnerships with a number of pharma
companies as well as commercial partnerships for its marketed
products.
Zealand was founded in 1998 and is headquartered in Copenhagen,
Denmark, with a presence in the U.S. For more information about
Zealand, please visit http://www.zealandpharma.com.
Contact:
Adam Lange
Investor Relations Officer
Zealand Pharma
Email: akl@zealandpharma.com |
|
Anna Krassowska,
PhD
Vice President, Investor Relations & Corporate
Communications
Zealand Pharma
Email: ank@zealandpharma.com |
- Zealand Pharma AS Disclosure Form TD 02.04.2024
- Zealand Pharma AS Disclosure Form TD 04.03.2024
- Zealand Pharma AS Disclosure Form TD 04.03.2024_Updated
- Zealand Pharma AS Disclosure Form TD 08.03.2024
- Zealand Pharma AS Disclosure Form TD 08.03.2024_Updated
- Zealand Pharma AS Disclosure Form TD 14.03.2024_Updated
- Zealand Pharma AS Disclosure Form TD 27.03.2024
Zealand Pharma AS (TG:22Z)
Historical Stock Chart
From Oct 2024 to Nov 2024
Zealand Pharma AS (TG:22Z)
Historical Stock Chart
From Nov 2023 to Nov 2024